Effects of norepinephrine and angiotensin II on plasma atrial natriuretic peptide concentration in humans. 1989

K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
Second Department of Internal Medicine, Sapporo Medical College, Japan.

To clarify the effects of norepinephrine and angiotension II (Ang II) on plasma atrial natriuretic peptide (ANP), both pressor substances were infused into normal volunteers, and plasma ANP levels and venous return were determined. When norepinephrine infusion elevated mean arterial pressure by 15 mm Hg, a transient increase of plasma ANP was observed. However, Ang II infusion showed no effect on plasma ANP levels, even though it also elevated arterial pressure. Superior vena cava flow and left atrial area, which were determined echocardiographically as the index of venous return, increased in the norepinephrine infusion study. However, in the study of Ang II infusion, there was no significant change in either superior vena cava flow or left atrial area. From these results, it was concluded that increased left atrial volume due to increased venous return is the major factor inducing ANP release in norepinephrine infusion.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
September 1991, American journal of obstetrics and gynecology,
K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
September 1992, Revista espanola de fisiologia,
K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
September 1986, The Journal of clinical endocrinology and metabolism,
K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
August 2001, British journal of clinical pharmacology,
K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
November 1992, European journal of pharmacology,
K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
December 1995, Hypertension research : official journal of the Japanese Society of Hypertension,
K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
September 1988, The American journal of physiology,
K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
October 2006, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine,
K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
June 1994, Glia,
K Shimamoto, and M Nakagawa, and S Fukuyama, and N Ura, and H Murakami, and S Yonekura, and M Iwakura, and Y Yamaguchi, and T Ise, and S Saitoh
September 1995, Biological & pharmaceutical bulletin,
Copied contents to your clipboard!